Babesiosis in humans: a treatment review

Bibliography

• HOMER MJ, AGUILAR-DELFIN I, TELFORD III SR et al.: Babesiosis. Clin. Microbial. Rev (2000) 13(3):451–469.
   Google Scholar
• ••This is an excellent comprehensive reviewof the subject.
   Google Scholar
• PRUTHI RK, MARSHALL WE WILTSIE JC, PERSING DH: Human babesisois. Mayo Clin. Proc. (1995) 70:853–862.
   PubMed Web of Science ®Google Scholar
• KJEMTRUP AM, CONRAD PA: Human babesiosis: an emerging tick-borne disease. Int. J. Thrash. (2000) 30:1323–1337.
   Web of Science ®Google Scholar
• ••An excellent review of human babesiosis,with a good discussion of newly identified species.
   Google Scholar
• WILSON LB, CHOWNING WM: Studies in Pyrop/asmosis &minis ('spotted fever' or 'tick fever' of the Rocky Mountains)." Infect Dis. (1904) 1:31–57.
   Google Scholar
• SKRABALO Z, DEANOVIC Z: Piroplasmosis in man. Doc. de Med. Georg. et Bop. (1957) 9:11–16.
   PubMedGoogle Scholar
• PERSING DH, HERWALDT BL, GLASER C et al.: Infection with a Babesia-like organism in northern California. N Engl. J. Med. (1995) 332:298–303.
   PubMed Web of Science ®Google Scholar
• •Description of new B. microti-like pathogens CA-1 strain.
   Google Scholar
• HERWALDT BL, SPRINGS F, ROBERTS PP et al: Babesiosis in Wisconsin: a potentially fatal disease. Am. J. Bop. Med. Hyg. (1995) 53:146–151.
   PubMed Web of Science ®Google Scholar
• •Description of new B. microti-like pathogens WA-1 strain.
   Google Scholar
• HERWALDT BL, LJEMTRUP AM, CONRAD PA et al.: Transfusion-transmitted babesiosis in Washingon State: first reported case caused by a WA-1 type parasite. J. Infect. Dis. (1997) 175(5):1259–1262.
   PubMed Web of Science ®Google Scholar
• WEI Q, TSUJL M, ZAMOTO A et al: Human babesiosis in Japan: isolation of Babesia microtilike parasites from an asymptomatic transfusion donor and from a rodent from an area where babesisois is endemic.' Gin. Microbial. (2001) 39(6):2178–2183.
   Google Scholar
• HERWALDT BL, PERSING DH, PRECIGOUT E et al.: A fatal case of babesiosis in Missouri: identification of another piroplasm that infects humans. Ann. Int. Med. (1996) 124:643–650.
   PubMed Web of Science ®Google Scholar
• •Description of the MO-1 strain that is related to B. divergens.
   Google Scholar
• KRAUSE PJ: Babesiosis. Med. Gin. N Am. (2002) 86:361–373.
   PubMedGoogle Scholar
• KRAUSE PJ, TEDFORD SR III, SPEILMAN A et al.: Concurrent Lyme disease and human babesiosis: evidence for increased severity and duration of illness. JAMA (1996) 275:1657–1660.
   PubMed Web of Science ®Google Scholar
• MEHLHORN H, SCHEIN E: The piroplasms: life cycle and sexual stages. Adv. Parasitol (1987) 23:37–103.
   Google Scholar
• RUEBUSH II TK, JURANEK DD, SPIELMAN A et al.: Epidemiology of human babesiosis on Nantucket Island. Am. J. Bop. Med. Hyg. (1981) 30:937–941.
   PubMed Web of Science ®Google Scholar
• KRAUSE PJ, SPEILMAN A, TEDFORD SR III et al: Persistent parasitemia after acute babesiosis. N Engl. J. Med. (1998) 339:160–165.
   PubMed Web of Science ®Google Scholar
• •Data on the persistence of Babesia using PCR. This paper shows that the organism may be present for a long time after symptoms abate.
   Google Scholar
• EBERHARD ML, WALKER EM, STEUER FJ: Survival and infectivity of Babesia in blood maintained at 25 and 24 C. J. Parasitol (1995) 81(5):790–792.
   PubMed Web of Science ®Google Scholar
• DOBROSYCKI J, HERWALDT B, BOCTOR F et al.: A cluster of transfusion-associated babesiosis cases traced to a single asymptomatic donor. JAMA (1999) 281 (10):927–930.
   PubMed Web of Science ®Google Scholar
• •This paper demonstrates the transmission of Babesia by blood products in a neonatal intensive care unit.
   Google Scholar
• GERBER MA, SHAPIRO ED, KRAUSE PJ et al.: The risk of acquiring Lyme disease or babesiosis from a blood transfusion. " Infect. Dis. (1994) 170:231–234.
   Google Scholar
• FRADIN MS: Mosquitoes and mosquito repellents: a clinician's guide. Ann. Intern. Med. (1998) 128:931–940.
   PubMed Web of Science ®Google Scholar
• ••An excellent review of the information onthe safety and use of DEET and other insect repellents.
   Google Scholar
• ROWIN KS, TANOWITZ HB, RUBENSTEIN A et al.: Babesiosis in asplenic hosts. Tian. R. Soc. Bop. Med. Hyg. (1984) 78:442–444.
   PubMed Web of Science ®Google Scholar
• WHITE DJ, TALARICO J, CHANG HG, BIRKHEAD GS, HEIMBEGER T, MORSE DL: Human babesiosis in New York state: review of 139 hospitalized cases and analysis of prognostic factors. Arch. Intern. Med. (1998) 158:2149–2154.
   PubMedGoogle Scholar
• FALAGAS ME, KLEMPNER MS. Babesiosis in patients with AIDS: a chronic infection presenting as fever of unknown origin. Gin. Infect. Dis. (1996) 22:809–812.
   PubMed Web of Science ®Google Scholar
• PERSING DH, MATHIESON D, MARSHALL WF et al.: Detection of Babesia microti by polymerase chain reaction. " Clin. Microbial. (1992) 30:2097–2103.
   Google Scholar
• GLEASON NN, HEALY GR, WESTERN KA et al.: The 'Gray' strain of Babesia microti from a human case established in laboratory animals. J. Parasitol (1970) 56:1256–1257.
   PubMed Web of Science ®Google Scholar
• BRASSEUR PS, LECOUBLET N, KAPEL L et al.: In vitro evaluation of drug susceptibilities of Babesia divergens isolates. Antimicrob. Agents Chemother. (1998) 42:818–820.
   PubMed Web of Science ®Google Scholar
• GRAY JS: Chemotherapy of Babesia divergens in the gerbil, Merones unguiculatus. Res. Vet. Sci. (1983) 35(3):318–324.
   PubMed Web of Science ®Google Scholar
• WITTNER M, LEDERMAN J, TANOWITZ HB et al.: Atovaquone in the treatment of Babesia microti infections in hamsters. Am. J. Bop. Med. Hyg. (1996) 55:219–222.
   PubMed Web of Science ®Google Scholar
• •Contains information on the development of resistance to atovaquone when used as monotherapy in the hamster model of babesiosis.
   Google Scholar
• HUGHES WT, OZ HS: Successful prevention and treatment of babesisois with atovaquone. " Infect. Dis. (1995) 172:1042–1046.
   PubMed Web of Science ®Google Scholar
• ROWIN KS, TANOWITZ HB, WITTNER M: Therapy of experimental babesiosis. Ann. Intern. Med. (1982) 97:556–558.
   PubMed Web of Science ®Google Scholar
• MILLER LH, NEVA F, GILL F: Failure ofchloroquine in human babesiosis (Babesia micron): case report and chemotherapeutic trials in hamsters. Ann. Intern. Med. (1978) 88:200–202.
   PubMed Web of Science ®Google Scholar
• MARCUS LC, MABRAY CJ, STURGIS GH: Babesia microti infection in the hamster: failure of quinine and pyrimethamine in chemotherapeutic trials. Am. J. Bop. Med. Hyg. (1984) 33:21–23.
   PubMed Web of Science ®Google Scholar
• MARLEY SE, EBERHARD ML, STEURER FJ et al.: Evaluation of selected antiprotozoal drugs in the Babesia microti-Hamster Model. Antimicrob. Agents Chemother: (1997) 41(1):91–94.
   PubMed Web of Science ®Google Scholar
• MILLER LH, NEVA FA, GILL F: Failureof chloroquine in human babesiosis (Babesia micron): case report and chemotherapeutic trials in hamsters. Ann. Intern. Med. (1978) 88:200–202.
   PubMed Web of Science ®Google Scholar
• WEISS LM, WITTNER M, WASSERMAN S et al.: Efficacy of Azithromycin for treating Babesia microti infection in the hamster model." Infect. Dis. (1993) 168:289–292.
   Google Scholar
• PUDNEY M, GRAY JS: Therapeutic efficacy of atovaquone against the bovine intraerythrocyfic parasite, Babesia divergens. Parasitol (1997) 83:307–310.
   Web of Science ®Google Scholar
• GRAY JS, PUDNEY M: Activity of atovaquone against Babesia microtiin the Mongolian gerbil Meriones unguiculatus. .1. Parasitol (1999) 85(4):723–728.
   Google Scholar
• RUEBUSH II TK, CONTACOSI PG, STECK EA: Chemotherapy of Babesia microBinfections in Mongolian birds. Antimicrob. Agents Chemother. (1980) 18:289–291.
   PubMed Web of Science ®Google Scholar
• KUTTLER KL, ZAUG JL, GIPSON CA: Imidocarb and paravaquone in the treatment of piroplasmosis (Babesia eqW in equids. Am. J. Vet. Res. (1987) 48:1613–1616.
   PubMed Web of Science ®Google Scholar
• ZAUGG JL, LANE VM: Evaluations of buparvaquone as a treatment for equine babesiosis (Babesia equij. Am. I Vet. Res. (1989) 50:782–785.
   PubMed Web of Science ®Google Scholar
• VERCAMMEN F, DEDEKEN R, MAES L: Prophylactic activity of imidocarb against experimental infection with Babesia cards Vet. Parsitol (1996) 63:195–198.
   Web of Science ®Google Scholar
• VERCAMMEN F, DEDEKEN R, MAES L: Prophylactic treatment of experimental canine babesisois (Babesia canis) with doxycycline. Vet. Parsitol (1996) 66:251–255.
   PubMed Web of Science ®Google Scholar
• CALLOW LL, DALGLIESH RJ, DEVOS AJ: Development of effective living vaccines against bovine babesiosis-the longest field trial? hat. I Parasitol (1997) 27(7):747–767.
   Web of Science ®Google Scholar
• •A good discussion of the use of vaccines in livestock for the prevention of babesiosis.
   Google Scholar
• RUEBUSH TK, RUBIN RH, WOLPOW ER et al.: Neurologic complications following the treatment of human Babesia microBinfection with diminazene acetate. Am. J. Bop. Med. Hyg. (1979) 28:184–189.
   PubMed Web of Science ®Google Scholar
• FRANCIOLI PB, KEITHLY JS, JONESTC et al.: Response of babesiosis to pentamidine therapy. Ann. Intern. Med. (1981) 94:326–330.
   PubMed Web of Science ®Google Scholar
• GORENFLOT A, BRASSEUR P, BOMMARCHAND G et al: Two cases of human babesiosis treated successfully. Presse Med. (1990) 19:335.
   PubMed Web of Science ®Google Scholar
• DENES E, ROGEZ JP, DARDE ML, WEINBRECK P: Management of Babesia divergens babesisois without a complete course of quinine treatment. Eur: Clin. Microbial. Infect. Dis. (1999) 18(9):672–673.
   PubMed Web of Science ®Google Scholar
• BRASSEUR P, LECOUBLET S, KAPELN, PAVENNEC L, BALLET JJ: Quinine in the treatment of Babesia divergens infections in humans. Eur: I Clin. Microbial. Infect. Dis. (1996) 15(10):840–841.
   PubMed Web of Science ®Google Scholar
• CENTER FOR DISEASE CONTROL AND PREVENTION: Clindamycin and quinine treatment for Babesia micron infection. MMWR Morb Mortal. Wdly Rep. (1983) 32(5):65–6, 72.
   Google Scholar
• WITTNER M, ROWIN DS, TANOWITZ HB et al.: Successful chemotherapy of transfusion babesiosis. Ann. Intern. Med. (1982) 96:601–604.
   PubMed Web of Science ®Google Scholar
• DORMAN SE, CANNON SR, TELFORD III SR et al.: Fulminant babesisois treated with clindamycin, quinine and whole-blood exchange transfusion. Transfusion (2000) 40:375–380.
   Google Scholar
• •An excellent literature review of the use of exchange transfusion as an adjunctive therapy for babesiosis.
   Google Scholar
• HATCHER JC, GREENBERG PD, ANTIQUE J, JIMENEZ-LUCHO VE: Severe babesiosis in Long Island: review of 34 cases and their complications. Clin. Infect. Dis. (2001) 32:1117–1125.
   PubMed Web of Science ®Google Scholar
• ••A large case series that contains excellentinformation on the management and outcome of babesiosis.
   Google Scholar
• BONOAN JT, JOHNSON DH, CUNHA BA: Life threatening babesiosis in an asplenic patient treated with exchange transfusion, azithromycin and atovaquone. Heart Lung (1998) 27:424–428.
   PubMed Web of Science ®Google Scholar
• CAHILL KM, BENACH LM, REICH E et al.: Red cell exchange: treatment of babesiosis in a splenectomized patient. Transfusion (1981) 21:193–198.
   PubMed Web of Science ®Google Scholar
• EVERSON DA, PERRY E, KLOSTER B et al.: Therapeutic apheresis for babesiosis. Clin. Apheresis (1998) 13:32–36.
   PubMed Web of Science ®Google Scholar
• JACOBY GA, HUNT JV, KOSINSKI KS et al.: Treatment of transfusion transmitted babesiosis by exchange transfusion. N Engl. J. Med. (1980) 303:1098–1100.
   PubMed Web of Science ®Google Scholar
• MACHTINGER L, TELFORD SR 3RD, INDUCIL C et al.: Treatment of babesiosis by red blood cell exchange in an HIV positive splenctomized patient. J. Clin. Apheresis. (1993) 8:78–81.
   Google Scholar
• SHIH CM, WANG CC: Ability of azithromycin in combination with quinine for the elimination of babesial infection in humans. Am. I Bop. Med. Hyg. (1998) 59(4):509–512.
   PubMed Web of Science ®Google Scholar
• SHAIO MF, YANG KD: Response of babesisois to a combined regimen of quinine and azithromycin. Trans. Royal Soc. Bop. Med. Hyg. (1997) 91:214–215.
   PubMed Web of Science ®Google Scholar
• KRAUSE PJ, LEP ORE T, SIKAND VK et al.: Atovaquone and azithromycin for the treatment of babesiosis. N Engl. .1. Med. (2000) 343(20):1454–1458.
   Google Scholar
• ••An important prospective, open, rand-omised trial of dindarnycin-quinine versus azithromycin-atovaquone. This study shows that atovaquone is an important drug for the treatment of babesiosis and confirms animal models and human case reports on the utility of atovaquone and azithromycin in babesiosis.
   Google Scholar
• WEISS LM, WITTNER M, TANOWITZ HB: The treatment of babesiosis. N Engl. J. Med. (2001) 344(10):773.
   PubMedGoogle Scholar
• •Comments on the utility of azithromycin and atovaquone in the treatment of babesiosis in neonates, the immunocompromised and the elderly.
   Google Scholar